Yeast-brachyury immunotherapeutic compositions
AssigneesGlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
InventorsClaudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
Life of this patent
Estimating the term…
Abstract
Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
Claims41
-105. (canceled)
A method to treat cancer in an individual, comprising administering to an individual who has cancer, an immunotherapeutic composition comprising:
- a) a yeast vehicle;
- and
- b) a cancer antigen comprising a Brachyury antigen, wherein the Brachyury antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, SEQ ID NO:18, positions 2-435 of SEQ ID NO:18, or an amino acid sequence that is at least 85% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine.
A method to treat cancer in an individual, comprising administering to an individual who has cancer, an immunotherapeutic composition comprising:
- a. a whole, inactivated yeast;
- and
- b. a Brachyury fusion protein comprising the amino acid sequence of positions 2-435 of SEQ ID NO:6 or the amino acid sequence of positions 2-435 of SEQ ID NO:18;
- wherein the Brachyury fusion protein is expressed by the yeast;
- and wherein the composition elicits a Brachyury-specific T cell response.
An immunotherapeutic composition comprising:
- a) a yeast vehicle;
- b) a cancer antigen comprising a Brachyury antigen, wherein the Brachyury antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, SEQ ID NO:18, positions 2-435 of SEQ ID NO:18, or an amino acid sequence that is at least 85% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine;
- and
- c) a pharmaceutically acceptable excipient suitable for administration to a human.
A recombinant nucleic acid molecule encoding a fusion protein comprising at least one Brachyury antigen, wherein the Brachyury antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, SEQ ID NO:18, positions 2-435 of SEQ ID NO:18, or an amino acid sequence that is at least 85% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine.
A fusion protein comprising at least one Brachyury antigen, wherein the Brachyury antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, SEQ ID NO:18, positions 2-435 of SEQ ID NO:18, or an amino acid sequence that is at least 85% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine.
A method to treat cancer in an individual, comprising administering to an individual who has cancer, an immunotherapeutic composition comprising:
- a) a yeast vehicle;
- b) a cancer antigen comprising a Brachyury antigen, wherein the Brachyury antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, SEQ ID NO:18, positions 2-435 of SEQ ID NO:18, or an amino acid sequence that is at least 85% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine;
- and
- c) an agent selected from the group consisting of an immunotherapeutic virus-based vaccine, a cytokine, a T-cell co-stimulator, a immunomodulator, CD40, anti-CTLA-4 antibody, anti-PD-1, anti-PD-L1, anti-PD-L2 and combinations thereof.
Dependencies are inferred from the claim text.